Related Experiment Video
Updated: Aug 16, 2026
08:48
Development of a Backbone Cyclic Peptide Library as Potential Antiparasitic Therapeutics Using Microwave Irradiation
Published on: January 26, 2016
Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. dessayan@welchlink.welch.jhu.edu
Biochemical Pharmacology
|May 5, 2000
Summary
Cyclic nucleotide phosphodiesterase (PDE) inhibitors, particularly PDE4 inhibitors, show promise as anti-inflammatory and immunomodulatory agents. Early clinical trials confirm their therapeutic potential but also reveal challenges in managing specific PDE isozyme inhibition.
Area of Science:
- Biochemistry
- Pharmacology
- Immunology
Background:
- Cyclic nucleotide phosphodiesterase (PDE) enzymes regulate intracellular cyclic nucleotide levels.
- PDEs are implicated in various disease states, making them therapeutic targets.
- Isozyme-selective inhibitors are being developed for targeted treatment.
Purpose of the Study:
- To review the current understanding of PDE inhibitors as immunomodulatory agents.
- To discuss the therapeutic potential of PDE4 inhibitors in inflammation.
- To highlight challenges in clinical applications of PDE inhibitors.
Main Methods:
- Review of in vitro and preclinical data on PDE inhibitors.
- Analysis of early clinical trial findings for selective PDE inhibitors.
- Examination of pharmacodynamic and toxicologic profiles of PDE isozyme inhibition.
Main Results:
- Extensive preclinical data support PDE4 inhibitors as potent anti-inflammatory agents.
- Early clinical trials validate the use of selective PDE inhibitors.
- Clinical trials identified pharmacodynamic and toxicologic issues associated with specific PDE isozyme inhibition.
Conclusions:
- PDE inhibitors, especially PDE4 inhibitors, are promising immunomodulatory agents.
- Further research is needed to overcome clinical challenges associated with PDE isozyme selectivity.
- Targeted PDE inhibition offers a potential therapeutic strategy for inflammatory diseases.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:34Inhibition of CDK Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...